A small-molecule program targeting GPR55 to address inflammatory pain and sickle-cell vaso-occlusive crises.
Therapeutic area
Inflammation & Hematology
Target
GPR55
Modality
Small Molecule
Ownership
Fully Owned
Lead Optimization2 of 7 to approval
Omic Discover · how this program was run: candidates screened, filtered and scored against the target. Open full size ↗
Why this program
01
A non-opioid pain mechanism
GPR55 is a G-protein-coupled receptor implicated in inflammation and pain signaling. Modulating it offers a potential route to treating inflammatory pain without relying on opioids.
02
Sickle-cell crises
Painful vaso-occlusive crises in sickle cell disease are driven in part by inflammation. A GPR55-targeted small molecule aims to reduce the frequency and severity of these episodes.
How we got here
01
AI-guided discovery
Omic’s AI scientists designed and prioritized GPR55-targeting molecules, scoring predicted response across patient backgrounds with Omic’s discovery models.
02
Where it stands
The program is in lead optimization, optimizing potency, selectivity, and oral drug-like properties.
Computational program. Laboratory and clinical validation are separate steps, and this program has not reached them. Request the current brief to review what has been run.
